Serum levels of miR-21, miR-23a, miR-142-5p, and miR-126 in chronic failure with reduced ejection fraction: a case-control study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111717" target="_blank" >RIV/00843989:_____/25:E0111717 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/25:A2603DAB

Result on the web

<a href="https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1529451/full" target="_blank" >https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1529451/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fcvm.2025.1529451" target="_blank" >10.3389/fcvm.2025.1529451</a>

Result language

angličtina

Original language name

Serum levels of miR-21, miR-23a, miR-142-5p, and miR-126 in chronic failure with reduced ejection fraction: a case-control study

Original language description

Background: MicroRNAs (miRNAs) are small non-coding RNA molecules that function as gene regulators in physiological processes, including proliferation, differentiation, and apoptosis. Various microRNAs have been linked to pathophysiological events associated with heart disease. In this case-control study, we investigated the levels of human miR-21, miR-23a, miR-142-5p, and miR-126 among heart failure patients with reduced ejection fraction (HFrEF), compared to healthy control participants. Methods: We prospectively enrolled clinically stable patients with heart failure (HF) and left ventricle ejection fraction (LVEF) ? 40%, and healthy individuals. MicroRNAs were analyzed from venous blood, using a microRNA enzymatic immunoassay (miREIA) method. Plasma miRNA levels were compared between HFrEF patients and healthy individuals, using non-parametric tests. Results: We enrolled 73 patients with HFrEF (86% males, mean age: 66.3 ± 10.7 years) and 99 healthy subjects (36% males, mean age: 44.7 ± 15.9 years). All four assayed miRNAs exhibited significantly higher median levels in heart failure patients compared to healthy controls: miR-21p, 243 pmol·l-1 vs. 14 pmol·l-1; miR-23a-3p, 705 pmol·l-1 vs. 119 pmol·l-1; miR-142-5p, 1,695 pmol·l-1 vs. 146 pmol·l-1; and miR-126-3p, 528 pmol·l-1 vs.21 pmol·l-1 (P ? 0.001 for all). The analyzed miRNA levels did not differ according to age, weight, height, or body mass index. No miRNA levels correlated with NTproBNP levels. Conclusion: Our findings revealed that the levels of miR-21-5p, miR-23a-3p, miR-142-5p,and miR-126-3p were significantly higher among HFrEF patients compared to healthy controls. Further exploration of these miRNAs may lead to new diagnostic, prognostic, and therapeutic options for HF patients.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in cardiovascular medicine

ISSN

2297-055X

e-ISSN

2297-055X

Volume of the periodical

12

Issue of the periodical within the volume

article 1529451

Country of publishing house

CH - SWITZERLAND

Number of pages

9

Pages from-to

1-9

UT code for WoS article

001497954300001

EID of the result in the Scopus database

2-s2.0-105006920125